FUJIFILM is the famous Corporate Investor, which was founded in 1934. The fund was located in Asia if to be more exact in Japan. The leading representative office of defined Corporate Investor is situated in the Tokyo.
Among the most popular portfolio startups of the fund, we may highlight Century Therapeutics, EdiGene, Lyndra Therapeutics. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Medical Device. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low.
The top activity for fund was in 2017. The real fund results show that this Corporate Investor is 30 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the FUJIFILM, startups are often financed by Polaris Partners, Yonghua Capital, Toray Industries. The meaningful sponsors for the fund in investment in the same round are SBI Investment, Cyberdyne, Yonghua Capital. In the next rounds fund is usually obtained by Lilly Asia Ventures, IDG Capital, WI Harper Group.
| Fund Name | Location |
| Arri | Bayern, Germany, Munich |
| Ashoka | Arlington, United States, Virginia |
| Beijing Jinhui Graham Investment Limited | Beijing, China, Haidian |
| C.Domain Capital | Beijing, Beijing, China |
| Clal Insurance Enterprises Holdings | Israel, Kiryat Gat, South District |
| Fame Mount Limited | - |
| Fuhai Yintao | China, Guangdong, Shenzhen |
| Future Group | Haryana, Haryana, India |
| Hirair and Anna Hovnanian Foundation | Armenia, Yerevan |
| Jiaxing Pucheng Gquan Touzi Hehuoqiye | China, Jiaxing, Zhejiang |
| Kingson Capital Partners | Durban, KwaZulu-Natal, South Africa |
| Norwegian Research Council | Norway, Oslo |
| Shefa Capital | Israel, Tel Aviv, Tel Aviv District |
| Shenzhen Dexin Ruihong Investment Center | China, Guangdong, Shenzhen |
| Skeleton Technologies | Estonia, Harjumaa, Tallinn |
| TechMinsk | Belarus, Minsk |
| Valquest Partners | Beirut, Beyrouth, Lebanon |
| Viva BioInnovator | China, Shanghai |
| W TOKYO | Japan, Kanagawa Prefecture, Kawasaki |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ripcord | $32M | 16 Apr 2024 | Hayward, California, United States | ||
Tome Biosciences | $213M | 12 Dec 2023 | Watertown, Massachusetts, United States | ||
Rege Nephro | $3M | 04 Jun 2020 | Kyoto, Kyoto Prefecture, Japan | ||
Nanox Imaging | $26M | 16 Jan 2020 | Yerushalayim, Center District, Israel | ||
Lunit | $4M | 30 Nov 2019 | South Korea, Gyeonggi-do, South Korea | ||
Century Therapeutics | $250M | 01 Jul 2019 | Philadelphia, Pennsylvania, United States | ||
PuREC | $5M | 19 Jun 2019 | Izumo, Shimane Prefecture, Japan | ||
LPIXEL | $27M | 28 Oct 2018 | Chiyoda, Japan | ||
Modalis Therapeutics | $4M | 20 Dec 2017 | Chiyoda, Japan |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ripcord | $32M | 16 Apr 2024 | Hayward, California, United States | ||
Tome Biosciences | $213M | 12 Dec 2023 | Watertown, Massachusetts, United States | ||
Rege Nephro | $3M | 04 Jun 2020 | Kyoto, Kyoto Prefecture, Japan | ||
Nanox Imaging | $26M | 16 Jan 2020 | Yerushalayim, Center District, Israel | ||
Lunit | $4M | 30 Nov 2019 | South Korea, Gyeonggi-do, South Korea | ||
Century Therapeutics | $250M | 01 Jul 2019 | Philadelphia, Pennsylvania, United States | ||
PuREC | $5M | 19 Jun 2019 | Izumo, Shimane Prefecture, Japan | ||
LPIXEL | $27M | 28 Oct 2018 | Chiyoda, Japan | ||
Modalis Therapeutics | $4M | 20 Dec 2017 | Chiyoda, Japan |
